After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Xenon Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Xenon Pharmaceuticals Inc is $3.09B. A total of 0.95 million shares were traded on the day, compared to an average of 393.12K shares.
In the most recent transaction, MORTIMER IAN sold 22,468 shares of XENE for 40.20 per share on Jan 24 ’25. After the transaction, the PRESIDENT & CEO now owns 31,302 company shares. In a previous transaction on Jan 27 ’25, MORTIMER IAN sold 16,315 shares at 40.50 per share. XENE shares that PRESIDENT & CEO owns now total 31,302.
Among the insiders who sold shares, MORTIMER IAN disposed of 16,217 shares on Jan 23 ’25 at a per-share price of $40.08. This resulted in the PRESIDENT & CEO holding 31,302 shares of XENE after the transaction. In another insider transaction, IAN MORTIMER bought 16,315 shares at $40.50 per share on Jan 27 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, XENE has a high of $50.99 and a low of $35.53.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $10.53, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.89.
